Benitec limited technology used by scientists at the University of Queensland, develop a treatment for cervical cancer

Current article ratings:
Patients / public:healthcare Prof:
Benitec limited (ASX: BLT) (PINK: BNIKF) today welcomed the publication of research by scientists at the University of Queensland, which demonstrated the value of the Benitec gene silencing platform technology for effective human Therapeutics for cancer. Their results were this month in the prestigious international scientific journal cancer gene therapy * published.

(* Reference: W gu, E Payne, Sun, M Burgess, NAJ McMillan.) Inhibition of cervical cancer cell growth in vitro and in vivo with dual ShRNAs. Cancer gene therapy (2011) 18, 219-227)

The researchers, not with Benitec, Benitec DNA used together are directed RNA interference (DdRNAi) technology in their cervix cancer research.

Dr. Peter French, CEO of B! Enitec said: "it's very gratifying to see, a further proof of the power of the Benitec's DdRNAi technology new therapies for, treatment and potential offer treatment of serious diseases such as cancer regardless are produced." "Benitec is pleased to facilitate our technology with major pharmaceutical companies on the partnership, DdRNAi-based therapeutics in the market for the benefit of the patients with a variety of disease bring conditions."

The researchers showed that cells in culture are quickly killed cervical cancer after treatment with DdRNAi in the form of two short hairpin of RNAs in a delivery vehicle linked with each other. This were used in the comparison to previous studies in which single short hairpin of RNAs with less impact and emphasised the potential commercial value of the development of DdRNAi.

Benitec of own DdRNAi-based R & D programmes in the areas of cancer-associated chronic pain, hepatitis B and drug resistant lung cancer! should in the proof of the efficacy and safety of the EC Treaty. Hnology, all gene silencing capable, associated with a serious life-threatening disease in man or medical condition.

Benitec is the DdRNAi platform technology for specific applications to biopharmaceutical companies, including the American Tacere Therapeutics, Inc., licensing, the Benitec of the technology for the development of a DdRNAi-based molecule for the treatment of hepatitis C virus infections, with successful preclinical results exclusively have licensed.

Scientific summary

The University of Queensland researchers shown that a multi-ShRNA strategy offers targeted human papillomavirus (HPV) E6/E7 oncogenes a more effective approach to the development of a DdRNAi therapy cervix cancer and possibly other cancers as a single ShRNA approach. The multi-ShRNA approach allows even synergistic or additive effects, rapid cell death to move before resistance has a chance to occur. The researchers data proves that dual ShRNA constructs effectively can! To bring key target genes in cancer cells to silence. This use of the technology has the additional advantage of targeting the several genes or pathways to cancer cells viability ability. The multi-target strategy will allow also the technology at the same time objective sleeping types a cancer-associated genes and make multiple copies of the ShRNA at different locations of the most important gene with a vector.

This strategy overcame two previously identified limitations of RNA interference based approaches in audience-based targeting cervix cancer cells - development of resistance to RNAi induced by synthetic SiRNA and short-term expression of the individual ShRNAs with lentivirus delivery.

How these constructs can be easily changed in the paper, a further one or two ShRNAs a triple or quadruple ShRNA add molecule. This (triple) approach is used, therapeutic Benitec's licensee Tacere Therapeutics Inc. for the development of a hepatitis C.

Source:
Benitec limited